Lastly, we used KLK6-expressing human PDAC cells to test a proteolysis-resistant KLK6 inhibitor and its effects on KLK6 expression; secretion; cell functions, for example cell proliferation and migration; and KLK6-interacting factors using a preclinical tumour spheroid model. This evidence concerns the gene KLK6 and neoplasm.